The purpose of this study is to find out what effects, good and/or bad, BIBW 2992 (Afatinib)
has on patients and their advanced prostate cancer which does not respond to hormone or
chemotherapy any more. Only patients with tumors which have an increased amounts of a protein
called HER2 on their cell surface will be included.
BIBW 2992 (Afatinib) is a drug which in advanced clinical testing in lung and breast cancer.